Pablo Umaña

18PUBLICATIONS
194CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Medical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jun 12, 2026
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

|Apr 21, 2026
FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors.

|Sep 17, 2025
PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer.

Irene Fusi, Clara Serger, Petra Herzig

|Apr 16, 2024
The physiological interactome of TCR-like antibody therapeutics in human tissues.

Estelle Marrer-Berger, Annalisa Nicastri, Angelique Augustin

|Mar 04, 2024
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Johannes Sam, Thomas Hofer, Christine Kuettel

|Feb 06, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

Solange Peters, Eric Angevin, Teresa Alonso-Gordoa

Pageof 3

Frequent Collaborators

16 joint publications

Christian Klein

4 joint publications

Laura Codarri Deak

4 joint publications

Johannes Sam

4 joint publications

Stefanie Briner